HONG KONG – Swedish biopharma Calliditas Therapeutics AB and Singapore-headquartered pharmaceutical company Everest Medicines II Ltd. agreed to develop and commercialize Nefecon for the treatment of IgA nephropathy in greater China and Singapore in a deal valued at more than $121 million.
HONG KONG – Aiming to expand its market in greater China, Cstone Pharmaceuticals Co. Ltd. submitted a new drug application (NDA) for Tibsovo (ivosidenib) to the Taiwan Food and Drug Administration (TFDA), seeking approval of the first drug to treat adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
HONG KONG – New results from a study of South Korean company Qurient Co. Ltd.'s orally available antibiotic, telacebec, suggest it is moving closer to offering a new therapeutic option for people with multidrug-resistant tuberculosis (MDR-TB).
HONG KONG – Aiming to expand its market in greater China, Cstone Pharmaceuticals Co. Ltd. submitted a new drug application (NDA) for Tibsovo (ivosidenib) to the Taiwan Food and Drug Administration (TFDA), seeking approval of the first drug to treat adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
HONG KONG – New results from a study of South Korean company Qurient Co. Ltd.'s orally available antibiotic, telacebec, suggest it is moving closer to offering a new therapeutic option for people with multidrug-resistant tuberculosis (MDR-TB). The company's phase IIa trial focused on early bactericidal activity (EBA) in MDR-TB, a form of the infection that does not respond to at least two of the most powerful anti-TB drugs, isoniazid and rifampicin.
HONG KONG – Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development focused on testing the combination of immune checkpoint inhibitors and small-molecule cancer drugs.
HONG KONG – Invossa-K, a first-in-class cell and gene therapy that made headlines in 2017 when South Korean regulators cleared its use to treat osteoarthritis of the knee, is now on the verge of being phased out of the domestic market at least for one year and possibly for good, after being hit by a scandal involving its component ingredients.
HONG KONG – Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development focused on testing the combination of immune checkpoint inhibitors and small-molecule cancer drugs.
